<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="362951">
  <stage>Registered</stage>
  <submitdate>28/08/2012</submitdate>
  <approvaldate>5/09/2012</approvaldate>
  <actrnumber>ACTRN12612000947808</actrnumber>
  <trial_identification>
    <studytitle>The role of  fluorescence in situ hybridization (FISH) in the early detection of bladder cancer using Photodynamic diagnosis  (PDD)</studytitle>
    <scientifictitle>The role of  fluorescence in situ hybridization (FISH) in the early detection of bladder cancer using PDD</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>bladder cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Bladder - transitional cell cancer</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>A multicolour-fluorescence in situ hybridization (FISH) approach will be performed on a liquid-based washing urinary cytology and on suspicious lesions in all participants. This will be performed once in all cases. The duration of fluorescence in situ hybridization and the histopathologic evaluation will be performed by our uro-pathologist. They will each last approximately two days. It will neither mean longer hospitalization nor more than the usual tissue specimens for all patients.</interventions>
    <comparator>no control group</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To investigate, whether through PDD identified and histologically diagnosed false-positive-lesions, are not indeed already anticipatory lesions with chromosomal aberrations.</outcome>
      <timepoint>The first results and primary outcomes will be assessed after twelve months.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Nil</outcome>
      <timepoint>Nil</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>urothelial carcinoma of the bladder</inclusivecriteria>
    <inclusiveminage>21</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>99</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>none</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Natural history</purposeobs>
    <duration>Cross-sectional</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/06/2013</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>50</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Bolzano (BZ)</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Central Hospital of Bolzano</primarysponsorname>
    <primarysponsoraddress>Lorenz-Boehler-Street 5
39100 Bolzano</primarysponsoraddress>
    <primarysponsorcountry>Italy</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Central Hospital of Bolzano</fundingname>
      <fundingaddress>Lorenz-Boehler-Street 5
39100 Bolzano</fundingaddress>
      <fundingcountry>Italy</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The percentage of the false positive lesions in photodynamic diagnosis (PDD) ranges between 7,1% and 47% in the literature. 
Careful interpretation and indication of PDD is necessary in case of previous instillation therapy especially with BCG and false positive rates of 64%.
Whether histologically proven false positive fluorescence is caused by early malignant genetic changes has been discussed but is still the object of research..</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Not yet submitted</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname />
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>1/01/2013</ethicsubmitdate>
      <ethiccountry />
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Thomas Martini</name>
      <address>Heinrich-Fuchs-Str. 103
69126 Heidelberg
Germany</address>
      <phone>+49(0)17631243718</phone>
      <fax />
      <email>tho.martini@yahoo.de</email>
      <country>Germany</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Thomas Martini</name>
      <address>Heinrich-Fuchs-Str. 103
69126 Heidelberg
Germany</address>
      <phone>+49(0)17631243718</phone>
      <fax />
      <email>tho.martini@yahoo.de</email>
      <country>Germany</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Thomas Martini</name>
      <address>Heinrich-Fuchs-Str. 103
69126 Heidelberg
Germany</address>
      <phone>+49(0)17631243718</phone>
      <fax />
      <email>tho.martini@yahoo.de</email>
      <country>Germany</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>